<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"><channel><title>RSS Feed on Applied Radiology</title><link>http://www.appliedradiology.com</link><description> RSS Feed on Applied Radiology</description><item><title>Spironolactone-induced gynecomastia</title><link>http://www.appliedradiology.com//Issues/2011/03/Cases/Spironolactone-induced-gynecomastia.aspx</link><description>&lt;p&gt;A 74-year-old man who underwent surgery for rectal cancer 2 years earlier
received a follow-up FDG-PET/CT examination. The study was performed with a Discovery
LS PET/CT camera (General Electric Medical Systems, Milwaukee, WI). Images were
obtained 50 min after intravenous injection of 185 MBq of FDG and performance of
CT-based attenuation correction. The acquisition and reconstruction parameters of the
FDG-PET scan were 2 min emission/bed, 7 bed position, and iterative reconstruction
(subset 14, number of iteration 2). The scanning parameters of the CT were Auto mA
(upper limit: 40 mA, noise index 20), 140kV, 5-mm section thickness, 15-mm table feed,
and a pitch of 4. The reconstructed images were converted to standardized uptake value
(SUV) images with patient’s body weight and injected dose of FDG. The patient had
a history of diabetes mellitus and liver cirrhosis with ascites; he had been taking a
potassium-holding diuretic, spironolactone, for 8 months. The patient also revealed
that he had been experiencing pain and swelling of the bilateral breast for a few
months immediately preceding the examination. &lt;/p&gt;</description><author></author><pubDate>Thursday, 24 Feb 2011 11:38:45 GMT</pubDate></item></channel></rss>